Matthew Paul Kowalsky - Feb 28, 2023 Form 3 Insider Report for Sigilon Therapeutics, Inc. (SGTX)

Role: CHIEF OF STAFF AND CLO
Signature: /s/ Matthew Kowalsky
Stock symbol: SGTX
Transactions as of: Feb 28, 2023
Transactions value $: $0
Form type: 3
Date filed: 3/1/2023, 03:35 PM
Next filing: Aug 11, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SGTX	Common Stock						19.7K	Feb 28, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SGTX	Stock Option (Right to Buy)							Feb 28, 2023	Common Stock	77.8K	$4.12	Direct	F2
holding	SGTX	Stock Option (Right to Buy)							Feb 28, 2023	Common Stock	1.11K	$9.39	Direct	F3
holding	SGTX	Stock Option (Right to Buy)							Feb 28, 2023	Common Stock	50K	$39.81	Direct	F4
holding	SGTX	Stock Option (Right to Buy)							Feb 28, 2023	Common Stock	90K	$3.03	Direct	F5
holding	SGTX	Stock Option (Right to Buy)							Feb 28, 2023	Common Stock	105K	$1.48	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 10,000 restricted stock units that vest as to 25% on October 29, 2023, which is the second anniversary of the date of grant, and 75% on the third anniversary of the date of grant, subject to the grantee's continued service to the Company on each vesting date.
F2	The option vested as to 25% of the underlying shares of common stock on May 6, 2020, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.
F3	The option vested as to 50% of the underlying shares of common stock on October 23, 2020, based on the Company's satisfaction of certain performance criteria. The option vested as to 50% of the underlying shares of common stock on October 23, 2021, the first anniversary of the vesting commencement date.
F4	The option vested as to 25% of the underlying shares of common stock on February 11, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.
F5	The option vested as to 30% of the underlying shares of common stock on January 3, 2023, the first anniversary of the vesting commencement date, and 70% on January 3, 2024.
F6	The option vested as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.